 |
- Nextstellis® (drospirenone/estetrol): The Next Big Thing in Birth Control
|
|
- Zegalogue® (dasiglucagon):A Sweet Medication to Treat Low Blood Sugar
|
|
- Quviviq® (daridorexant): Sweet Dreams in the Setting of Chronic Insomnia
|
|
- Using the PAK to Fight Back: Combating Helicobacter Pylori Infections with Novel Therapy
- Personalized Medicine Corner— CYP2C19 Polymorphisms in Clopidogrel Use for Patients with Peripheral Artery Disease
|
|
- Overview of Current Evidence for Using Pharmacogenetic Testing to Guide Warfarin Initial Dose Selection
|
|
- Mounjaro® (Tirzepatide): A Sweeter Outlook for Patients with Type 2 Diabetes
|
|
- Kerendia® (finerenone): Slowing the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes
|
|
- How Smart is Technology?: Understanding the Role of Clinical Decision Support in the Primary Care Setting
|
|
- The Clot Thickens: Is There Enough Evidence to Use Direct Oral Anticoagulants in Antiphospholipid Syndrome?
|
|
- Qulipta® (Atogepant): Taking the Headache Out of Migraine Prevention
|
|
- Verquvo® (vericiguat): One-A-Day Keeps the Hospital Away
- Personalized Medicine Corner�An Update to Medicare Coverage for Pharmacogenomics Testing
|
|
- Wegovy® (semaglutide): A Once-Weekly Weight Loss Injectable
|
|
- Review of the 2020 American Psychiatric Association Schizophrenia Treatment Guidelines
|
|
- Clostridioides is Not so Difficile with New Agents: A Review of the 2021 Update to the IDSA Clostridioides difficile Guidelines
- Personalized Medicine Corner� Venlafaxine and CYP2D6
|
|
- Brexafemme® (ibrexafungerp): A Novel Drug to Knock Out Vulvovaginal Candidiasis
|
|
- Cabenuva® (cabotegravir/rilpivirine): Injecting New Life into Treatment of Human Immunodeficiency Virus
|
|
- Pondering Ponvory® (Ponesimod): Preparing for Multiple Sclerosis
|
|
- Gemtesa® (Vibegron): Freeing Patients from Overactive Bladder
|
|
- Zokinvy® (lonafarnib): Giving More Years of Life to the Old Children
|
|
- Klisyri® (tirbanibulin): Itching for an answer to actinic keratosis
|
|
- Imcivree® (setmelanotide): A Small Injection Leading to Big Weight Loss
- Personalized Medicine Corner�Using the FDA Table of Pharmacogenetic Associations
|
|
- Primary Aldosteronism: An Underdiagnosed and Undertreated Cause of Hypertension
|
|
- Rukobia® (fostemsavir): Attempting to put the ART backing into antiretroviral therapy
|
|
- Veklury® (remdesivir): Will mediocrity suffice in a pandemic?
- Personalized Medicine Corner� Pharmacogenomics: TPMP and NUDT15 in Inflammatory Bowel Disease
|
|
- Accrufer® (ferric maltol): A Novel Oral Iron Replacement Product for the Treatment of Iron Deficiency in Adults
|
|
- Dayvigo® (lemborexant): Putting unsafe insomnia treatment to bed
|
|
- Pizensy® (Lactitol) attempts to loosen the market in its treatment for Chronic Idiopathic Constipation
- Personalized Medicine Corner— Pharmacogenomics: Proton Pump Inhibitors and CYP2C19
|
|
- Ongentys® (Opicapone): A Drug Lighting a New Path for Treatment of Parkinson�s Disease
|
|
- Ubrelvy® (ubrogepant): Adding to the Abortive Therapy Arsenal for Mi- graine Treatment
|
|
- Fetroja® (cefiderocol): A Modern Day Trojan Horse of Urinary Tract Infections
- Personalized Medicine Corner: Pharmacogenetics of NSAIDs and CYP2C9
|
|
- Caplyta® (lumateperone): A Unique, New Therapy Option for the Treatment of Schizophrenia.
- Editor�s corner: NDMA Impurities Continue
|
|
- Ervebo® (ebola zaire vaccine, live/rVSV?G- ZEBOV-GP ); Post-Epidemic Use Approval
|
|
- Nourianz® (istradefylline): A New Way to Switch Off Parkinson's
- Personalized Medicine Corner: Using Pharmacogenetic Testing to Inform Atomoxetine Therapy
|
|
- Xcopri® (cenobamate); Attempts to Seize a Place in Therapy for Epilepsy
|
|
- Rybelsus® (oral semaglutide); An Easy Pill to Swallow in a Class of Injectables
|
|
- Evenity® (romosuzumab-aqqg); A Novel Agent for Osteoporosis in Postmenopausal Women at High Risk for Fracture
- Personalized Medicine Corner: Pharmacogenetic Testing to InformCurrent and Future Drug Therapy
|
|
- Spravato® (Esketamine): An Old Drug With A New Indication For Major Depressive Disorder
|
|
- Sunosi® (Solriamfetol): A Novel Agent for Sleepiness in Narcolepsy or Obstructive Sleep Apnea
- Editors Corner: Drug Impuri- ties in News Headlines
|
|
- Continuous Blood Glucose Monitoring: Is There a Proven Benefit?
- Personalized Medicine Corner
- Index of Volume 34
|
|
- Yupelri® (Revefenacin): The Only Nebulized Once-Daily Long-Acting Muscarinic Antagonist for Chronic Obstructive Pulmonary Disease
|
|
- Omadacycline: Cycling Past the Competition?
|
|
- Prucalopride: The Only Prokinetic Chronic Idiopathic Constipation Treatment in the United States
- Using Pharmacogenetic Testing to Guide Antidepressant Selection: A Patient Case
|
|
- Baloxavir marboxil (XOFLUZA®) and the Management of Uncomplicated Influenza
|
|
- Ajovy™ (Fremanezumab): A New Preventive Treatment of Migraines in Adults
- Emgality® (Galcanezumab): A New Treatment for Preventing Migraines
|
|
- Overview of the 2018 CHEST Guideline for Stroke Prevention in Patients with Atrial Fibrillation
- Using Pharmacogenetics to Guide Proton Pump Inhibitor Dosing: A Patient Case
|
|
- Lucemyra® (Lofexidine): First Non-Opioid Approved for the Management of Acute Opioid Withdrawal
|
|
- Management of Stable COPD: Overview of Combination Inhalers LABA/LAMA and LABA/ICS
- Editor�s Corner: 2018 Update to the AHA/ACC Cholesterol Management Guidelines
|
|
- Lokelma® (sodium zirconium cyclosilicate): A Novel Agent for Chronic Hyperkalemia Management
- Personalized Medicine Corner: Incorporating Pharmacogenetics to Provide Drug Therapy Recommendations for Post-Operative Pain Management Following Total Knee Arthroplasty
|
|
- Aimovig®: A Novel Therapy for Preventive Treatment of Migraine
|
|
- Steglatro® (ertugliflozin): A New SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
|
|
- Andexanet Alfa: The First Factor Xa Inhibitor Reversal Agent
- Personalized Medicine Corner
- Index of Volume 33
|
|
- Semaglutide (Ozempic®): A New GLP-1 Agonist for Type 2 Diabetes Mellitus
|
|
- Latanoprostene Bunod (Vyzulta®): A New Ophthalmic Agent for Open-Angle Glaucoma and Ocular Hypertension
- Secnidazole (Solosec®): A New Single-Dose Treatment for Bacterial Vaginosis
|
|
- Plecanatide (Trulance®): A New Guanylate Cyclase-C Agonist for CIC and IBS-C
- Personalized Medicine: Genotype-Guided Opioid Prescribing
|
|
- Delafloxacin: A New Fluoro- quinolone for Acute Skin and Soft Tissue Infections
|
|
- Betrixaban: A New Oral Anticoagulant for Extended-Duration Thromboprophylaxis
|
|
- Shingrix®: A New Herpes Zoster Subunit Vaccine
- Personalized Medicine Corner: Pharmacogenetics and Tamoxifen in the Treatment of Breast Cancer
|
|
- Abaloparatide (Tymlos®): A New Agent to Prevent Ver- tebral Fractures in Women with Osteoporosis
|
|
- Sarilumab (Kevzara®): A New Treatment for Rheu- matoid Arthritis
|
|
- Naldemidine (Symproic®): A New Treatment for Opioid-Induced Constipation
- Personalized Medicine Corner: Patient Case� Pharmacogenetics in Primary Care
|
|
- Vitamin D Supplementation to Rechallenge Statin Therapy in Patients with Statin-Induced
Myalgia
|
|
- Dupilumab (Dupixent®): A Novel Agent for Atopic Dermatitis
- Editor�s Corner: Canagliflozin (Invokana®) Boxed Warning Update
|
|
- Combination GLP-1 Agonist and Basal Insulin for the Management of Type 2 Diabetes Mellitus
- Personalized Medicine Corner
- Index of Volume 32
|
|
- Management of Atopic Dermatitis with Synbiotics
- Editor�s Corner: Rates of Hypoglycemia and Insulin Degludec: Updates from Clinical Trials
|
|
- Eucrisa® (crisaborole): A New Top- ical Agent for the Treatment of Atopic Dermatitis
- Editor�s Corner: The VAST-D Ran- domized Clinical Trial
|
|
- New Evidence About an Old Drug: Role of Digoxin in Atrial Fibrillation
- Once Versus Twice-Daily Dosing of Insulin Glargine: A Comprehensive Review of the Literature
- Personalized Medicine Corner
|
|
- Single Maintenance and Reliever Therapy (SMART) for Asthma Control
- A Review of Antiplatelet Therapy in Secondary Stroke Prophylaxis
|
|
- Lixisenatide (Adlyxin®): A New GLP-1 Agonist for Type 2 Diabetes Mellitus
|
|
- Pharmacologic Treatment of Orthostatic Hypotension
- Personalized Medicine Corner
|
|
- Migraine Prophylaxis: A Review of Current and Future Therapies
- Evolocumab (Repatha®): A New Agent for Treatment of Hyperlipidemia
|
|
- Lifitegrast (Xiidra®): A Novel Treatment for Dry Eye Disease
|
|
- Brivaracetam (Brivact®): A New Adjunctive Treatment for Partial- Onset Seizures
- Personalized Medicine Corner
|
|
- Tiotropium/olodaterol (Stiolto®): A new fixed-dose combination thera- py for moderate-to-severe COPD
|
|
- Eluxadoline (Viberzi®): A Novel Agent for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
|
|
- Pseudoephedrine and Phenylephrine for Treatment of Nasal Congestion: A Comprehensive Review of Efficacy and Safety
- Personalized Medicine Corner
- Index of Volume 31
|
|
- Sumatriptan for Treatment of Migraines: Focus on Onzetra Xsail® (sumatriptan intranasal powder)
|
|
- Bexsero®: A New Vaccine Approved For Serogroup B Neisseria Meningitidis
|
|
- Intensive versus Standard Blood Pressure Goals for Treating Hypertnesion: A Review of Recent Landmark Trials
- Personalized Medicine Corner
|
|
- Enstilar® (calcipotriene and betamethasone dipropionate): A new topical agent for the treatment of plaque psoriasis
|
|
- Pharmacologic Treatment of Gout Now and in the Future
|
|
- Idarucizumab (Praxbind®): A Novel Direct Thrombin Inhibitor Reversal Agent
- Personalized Medicine Corner
|
|
- Umeclidinium (Incruse Ellipta®): A Long- Acting Muscarinic Antagonist for the Treatment of COPD
- Indacaterol/glycopyrrolate (Utibron TM Neohaler®): A New Maintenance Treat- ment for COPD
|
|
- Insulin degludec (Tresiba®): Ultra-long basal insulin with less nocturnal hypoglycemia than glargine
|
|
- Ivabradine (Corlanor®): A novel agent to reduce hospitalization due to worsening heart failure
- Personalized Medicine Corner
|
|
- Sacubitril/Valsartan (Entresto®): A New Dual Therapy Approved for Chronic Heart Failure
|
|
- Omega-3 Fatty Acids for Hypertriglyceridemia: Focus on Epanova®
- Alirocumab (Praluent®), a PCSK9 Inhibitor for Reducing Cardiovascular Risk: Balancing Efficacy and Expenditures
|
|
- Nicotine Replacement Therapy (NRT) in Pregnancy
- Index of Volume 30
- Personalized Medicine Corner
|
|
- Fluticasone Furoate: A Once Daily Inhaled Corticosteroid for the Treatment of Asthma
- Liraglutide (Saxenda®) Familiar Name, New use for Weight Management
|
|
- Olodaterol (Striverdi® Respimat®): A New Once-Daily Long-Acting ?- Agonist for the Treatment of COPD
|
|
- Efinaconazole (Jublia®): A New Topical Therapy for Toenail Onychomycosis
- Personalized Medicine Corner
|
|
- Peramivir: A Novel Intravenous Neuraminidase Inhibitor for the Treatment of Influenza
- Ceftolozane/tazobactam (Zerbaxa®) for Treatment of Complicated Urinary Tract Infections and Intra-abdominal Infections
|
|
- Edoxaban: A New Target Specific Oral Anticoagulant and It´s Place in a New and Growing Class
- Dulaglutide: A New GLP-1 Receptor Agonist for the Treatment of Diabetes
|
|
- Oralair®, Ragwitek®, and Grastek®: Novel Approaches to Treating Pollen-Induced Allergic Rhinitis
- Personalized Medicine Corner: Tramadol: Is toxicity risk affected by genotype?
|
|
- Empagliflozin (Jardiance®), A New SGLT2 Inhibitor to Treat Type 2 Diabetes: Third Time's A Charm?
|
|
- Oritavancin for Adults with Acute Bacterial Skin and Skin Structure Infections
|
|
- Oxycodone/naloxone (Targiniq ER®): A new option for chronic pain control
- Personalized Medicine Corner: Opioids & Genetic Testing
|
|
- Suvorexant (Belsomra®): A New Treatment Option for Insomnia
|
|
- Afrezza® (Technosphere® Insulin Inhalation System): Rapid-Acting Inhaled Insulin for the Treatment of Diabetes
- Contrave® (naltrexone HCl/bupropion HCl): The Newest Combination Weight Loss Treatment
|
|
- Vorapaxar (Zontivity®) for Secondary Prevention of Thrombotic Cardiovascular Events
- Index of Volume 29
- PharmaNote® Throwback Vol. 1, No. 1
- Personalized Medicine Corner
|
|
- Tedizolid Phosphate: A New Antimicrobial Agent Against MRSA
|
|
- Dalbavancin: A Novel Treatment for Acute Bacterial Skin and Skin- Structure Infections
|
|
- Albiglutide: A New Treatment Option for Type II Diabetes
- Zohydro®: Extended-release Hydrocodone: A Review
|
|
|
|
- 2013 ACCF/AHA Guidelines for the Management of Heart Failure: Expanded Use of Natriuretic Peptides and Aldosterone Antagonists
|
|
- Linaclotide: A New Option for Irritable Bowel Syndrome with Constipation (IBSC)
|
|
- Vortioxetine (Brintellix®): A Review
- Aptiom® (Eslicarbazepine acetate): A Review
|
|
- Duavee® (conjugated estrogens/ bazedoxifene): A review
|
|
- A Review of Non-hormonal Treatment Options for the Vasomotor Symptoms of Menopause with Emphasis on Brisdelle® (Paroxetine mesylate) and Serada® (Gabapentin ER)
|
|
- Anticoagulant Pharmacotherapy in Obese Patients
|
|
- Fluticasone Furoate/Vilanterol: A New Inhaled Corticosteroid/ Long-Acting Beta Agonist
- Levomilnacipran: New SNRI for the Treatment of Major Depressive Disorder
|
|
- Osteoporosis Management Update: Comparing the 2010 and 2013 National Osteoporosis Foundation Guidelines
- Index of Volume 28
|
|
- A Review of Aldosterone Antagonists in Diastolic Heart Failure
- Tapentadol Extended-Release for Painful Diabetic Peripheral Neuropathy
|
|
- Aclidinium: A New Long-acting Anti-cholinergic Inhaler for COPD
- Canagliflozin: A New Type 2 Diabetes Drug with a Novel Mechanism of Action
|
|
- A Review Of Intranasal Corticosteroids For The Treatment Of Allergic Rhinitis
- Ospemifene: A SERM For The Treatment Of Postmenopausal Dyspareunia
|
|
- Perampanel: The First AMPA Receptor Antagonist
- Alogliptin: A New Dipeptidyl- Peptidase-4 Inhibitor
|
|
- Off-Label Use Of Modafinil In Depression
|
|
- Guidelines For Atrial Fibrillation Management: Role Of The Affirm Trial
- Vascepa: A New Fish Oil For Severe Hypertriglyceridemia
|
|
|
|
- The New IDSA Recommendations For Acute Bacterial Rhinosinusitis: Empiric Antibiotic Therapy In Adults
- Teriflunomide: A New Option In Multiple Sclerosis
|
|
|
|
|
|
|
|
- Qnasl® (Beclomethasone Diproprionate)
- Avanafil (Stendra®): The Newest Phosphodiesterase 5 Inhibitor
|
|
- Two New Drugs for Obesity: A Review
|
|
|
|
|
|
- Rivaroxaban: The First Fda Approved Oral Directed Factor Xa Inhibitor
|
|
- Vilazodone: A New Treatment For Major Depressive Disorder
- An Update On The Treatment Of Gout: Focus On Febuxostat’s Role In Therapy
|
|
|
|
- Indacaterol Maleate: A New Once Daily Treatement Option for Chronic Obstructive Pulmonary Disease
- Ranolazine: A New Treatment for Chronic Angina
|
|
|
|
|
|
|
|
- An Update And Review Of Isoniazid In Tuberculosis
|
|
- Linagliptin: A New Option In The Treatment Of Type-Ii Diabetes
- Ezogabine: A New Option In The Treatment Of Partial Seizures
|
|
- Roflumilast: A New PDE4 Inhibitor For COPD
|
|
|
|
- Ceftaroline: A New Cephalosporin With Activity Against Methicillin-Resistant Staphylococcus Aureu
|
|
- Ulipristal Acetate (Ella®): A New Emergency Contraceptive
- Azilsartan Medoxomil: An Overview Of Safety And Efficacy
|
|
|
|
|
|
|
|
|
|
|
|
-
Helicobacter Pylori Positive Peptic Ulcer Disease: Antibiotic Resistance To First Line Therapy
- Denosumab (Prolia®): Twice-Yearly Treatment For Osteoporosis
|
|
-
Natazia®: A New Combination Oral Contraceptive
- Jalyn® (Dutasteride/Tamsulosin): A New Option In BPH
|
|
- Adverse Skeletal Effects Of Bisphosphonates: A Review
- Continuous Subcutaneous Insulin Infusion Vs. Multiple Daily Injections: A Review
- Index For Volume 25 (Oct. 2009 - Sep 2010)
|
|
- Ustekinumab: A New Treatment Approach For Psoriasis
|
|
- Liraglutide: A Newly Approved Incretin Mimetic
- Pitavastatin: A New Statin To Treat Hyperlipidemia
|
|
|
|
- Telavancin: A Lipoglycopeptide For The Treatment Of Complicated Skin And Skin Structure Infections
- Valturna® (Aliskiren/Valsartan): A New Combination Raas Inhibitor
|
|
|
|
|
|
- Cycloset®: A Unique Approach To Treating Diabetes
- Once Daily Aminoglycosides: A Review And Update
|
|
|
|
|
|
- Management Of Acne Vulgaris: A Review
- Dronedarone: A New Option For Atrial Fibrillation
|
|
|
|
- Pharmacokinetic Variability In Pregnancy And Proposed Labeling Changes
- Index For Volume 24 (Oct. 2008 - Sep. 2009)
|
|
|
|
|
|
- Milnacipran: A New Agent For Fibromyalgia
|
|
- Update On Statins: Focus On Unapproved Uses
|
|
- Managing Gestational Diabetes: A Review
|
|
- Zoledronic Acid: Once-Yearly Treatment For Osteoporosis
|
|
- The Management Of Neurodegenerative Symptoms In
Huntington’s Disease
|
|
- Zygomycosis: An Update On Treatment Options
|
|
- The Role Of Probiotics In The Prevention Of Antibiotic-Associated
Diarrhea
|
|
- An Update On Antiepileptic Agents: Focus On Second
Generation Treatment Options
- Index For Volume 23 (Oct. 2007—Sep. 2008)
|
|
- Diagnosis And Management Of Infectious Sinusitis
|
|
- Treximet® (Sumatriptan And Naproxen): The First
Combination Triptan/Nsaid For Acute Migraine
- Resistant Urinary Tract Infections
|
|
- Using Genetics To Drive Treatment: A Focus On Warfarin
|
|
- Desvenlafaxine (Pristiq®): A Selective Serotonin
And Norepinephrine Reuptake Inhibitor
- A Review Of Current Alzheimer’s Disease Pharmacotherapy
|
|
- Alternative Medicines Update: A Focus On The Most
Common Products Your Patients Are Using
|
|
- New Drugs Approved In 2007
|
|
- Exforge®: A New Combination To Treat Hypertension
- Maraviroc (Selzentry®): A Novel Antiretroviral
|
|
- Doripenem: The Newest Member Of The Carbapenem Family
|
|
- Budesonide And Formoterol (Symbicort®): A Review
|
|
- Rotigotine (Neupro®): The First Transdermal
Dopamine Agonist For Parkinson’s Disease
- Pharmacotherapy Of Onychomycosis: A Focus On Terbinafine
|
|
- A Review Of Acute Stress Ulcer Prophylaxis In The
Intensive Care Unit
- Index For Volume 22 (Oct. 2006—Sep. 2007)
|
|
- Lubiprostone (Amitiza®): The First Chloride
Channel Activator For The Treatment Of Chronic Idiopathic
Constipation
- Alli®: An Over-The-Counter Orlistat
|
|
- Review Of Fibric Acid Derivatives In Primary And
Secondary Prevention Of Coronary Heart Disease
|
|
- Tolvaptan: A New Approach To The Management Of Euvolemic
And Hypervolemic Hyponatremia
|
|
- Rotateq®: A Pentavalent Human-Bovine Rotavirus
Vaccine
|
|
- Posaconazole (Noxafil®): A New Broad Spectrum
Triazole Antifungal
|
|
- Phenylephrine For Pseudoephedrine In Otc Cold Medicines:
An Equal Exchange?
- Overview Of Triptans In The Management Of Acute
Migraine
|
|
- Aliskiren: A Direct Renin Inhibitor
|
|
- The Role Of Digoxin In Treating Systolic Heart Failure:
An Update
- Traditional Vs. Low-Dose Oral Contraceptives
|
|
|
